Topic

Michigan

A collection of 504 issues

How to Get Kesimpta (Ofatumumab) Covered by Aetna (CVS Health) in Michigan: Complete Prior Authorization and Appeals Guide

Quick Answer: Getting Kesimpta Covered by Aetna (CVS Health) in Michigan Aetna (CVS Health) requires prior authorization for Kesimpta (ofatumumab) in Michigan, typically after failure of 2-3 formulary disease-modifying therapies including an interferon or glatiramer acetate. Your neurologist must document relapsing MS diagnosis, prior therapy failures, hepatitis B screening, and
5 min read

How to Get Vitrakvi (Larotrectinib) Covered by Cigna in Michigan: Complete PA Guide and Appeal Scripts

Answer Box: Getting Vitrakvi Covered by Cigna in Michigan Vitrakvi (larotrectinib) requires prior authorization from Cigna for NTRK fusion-positive solid tumors that are metastatic or unresectable. Submit PA via CoverMyMeds or Evicore with molecular pathology report confirming NTRK fusion, oncologist prescription, and tumor staging documentation. If denied, Michigan residents have
5 min read

How to Get Spinraza (nusinersen) Covered by UnitedHealthcare in Michigan: Complete PA Guide and Appeals Process

Quick Answer: Getting Spinraza Covered by UnitedHealthcare in Michigan UnitedHealthcare requires prior authorization (PA) for Spinraza (nusinersen) with strict genetic and clinical documentation. Submit genetic confirmation of 5q SMA, baseline motor function scores (HFMSE/RULM), and neurologist prescription through the UHC provider portal. If denied, you have 180 days for
6 min read

Renewing Bavencio (Avelumab) Approval with Blue Cross Blue Shield Michigan: Complete Documentation Guide

Answer Box: Renewing Bavencio Coverage in Michigan Bavencio (avelumab) requires prior authorization renewal from Blue Cross Blue Shield of Michigan through their Oncology Value Management program managed by OncoHealth. Submit renewal requests 30-45 days before your current authorization expires using updated medical necessity documentation, recent imaging results, and treatment response
6 min read